Michael Midmer, CEO of Zucara Therapeutics, is confirmed to present at the 10th Annual Biotech Showcase. This important investor and
JDRF Funds Zucara Therapeutics’ Approach to Preventing Hypoglycemia in People with Type 1 Diabetes
NEW YORK, USA and TORONTO, Canada, September 21, 2017 — As Global Biotech Week begins in more than 20 countries,
Zucara Therapeutics Appoints Luc Mainville as Board Chair
VANCOUVER and TORONTO, Canada — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to
Dr. Claude Piché joins Zucara’s Board of Directors
VANCOUVER and TORONTO, Canada (July 10, 2017) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term
Zucara: a company that is “Ready to Rocket”
On March 3, 2017 Rocket Builders announced its 15th annual “Ready to Rocket” lists. These lists profile British Columbia technology companies that
Zucara’s Scientific Advisory Board Chair Co-Published in The Lancet
New paper published in The Lancet Diabetes & Endocrinology recommends exercise guidelines for type 1 diabetes patients and healthcare providers.
BC Health Minister Issues Statement for Diabetes Awareness Month
For Immediate Release BC Ministry of Health Diabetes Awareness Month: diabetes research VICTORIA – Health Minister Terry Lake has issued the
Zucara Therapeutics Receives Cash Injection to Advance Novel Diabetes Drug Therapy to Prevent Hypoglycemia
Zucara announced it has received a $525,000 investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research
Zucara Therapeutics & CDRD Complete Licensing Deal to Select Lead Therapeutic Drug Candidate
This new license is an important step forward in bringing a new drug therapy closer to patients living with diabetes
Zucara Therapeutics Appoints Michael Midmer as CEO
VANCOUVER and TORONTO, Canada (September 9, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term